MedPath
HSA Approval

REGPARA TABLETS 25 MG

SIN13993P

REGPARA TABLETS 25 MG

REGPARA TABLETS 25 MG

August 2, 2011

KYOWA KIRIN ASIA PACIFIC PTE. LTD.

KYOWA KIRIN ASIA PACIFIC PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantKYOWA KIRIN ASIA PACIFIC PTE. LTD.
Licence HolderKYOWA KIRIN ASIA PACIFIC PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION** The starting dosage for adults is 25 mg of cinacalcet once daily, to be orally administered. With careful management of the patient's serum parathyroid hormone (PTH) and calcium levels, the dose may then be adjusted within a range of 25–75 mg once daily. If no improvement found in PTH, the dose may be increased up to 100 mg once daily. If dose increase is required, dose should be increased by 25 mg at a time, at intervals of at least 3 weeks. **<Precautions related to Dosage and Administration>** 1. Regpara has an effect of decreasing calcium in blood. Therefore, it should be confirmed that the patient's serum calcium level is not low (9.0 mg/dL (2.3mmol/L or more) prior to administration. 2. The serum calcium level should be determined once a week at the start of administration and during the dose adjustment period, and at least once every two weeks during the maintenance period. If serum calcium level decreases to 8.4 mg/dL (2.1mmol/L) or less, the following measures should be taken. ![Regpara Dosage Table 1](Regpara-Table1_060423.png) The serum calcium level should be determined before administration of Regpara so that the effect and safety of the drug may be properly evaluated. Furthermore, it is recommended that corrected serum calcium valuesNote) should be used as a guide in patients with hypoalbuminemia (serum albumin: <4.0 g/dL). 3. The serum PTH level should be periodically determined so that it may be maintained at the target level for management. It is recommended that the serum PTH level should be determined twice a month at the start of administration and during the dose adjustment period (about 3 months after the start of administration), and at least once a month after the serum PTH level is confirmed to be almost stable. The serum PTH level should be determined before administration of Regpara so that the effect and safety of the drug may be properly evaluated. (Note) Corrected serum calcium is calculated as follows: Corrected serum calcium (mg/dL) = Serum calcium (mg/dL) − Serum albumin (g/dL) + 4.0

ORAL

Medical Information

**INDICATIONS** Secondary hyperparathyroidism in patients undergoing maintenance dialysis.

**CONTRAINDICATIONS (Regpara is contraindicated in the following patients.)** Patients with a history of hypersensitivity to any of the ingredients in Regpara.

H05BX01

cinacalcet

Manufacturer Information

KYOWA KIRIN ASIA PACIFIC PTE. LTD.

Ohara Pharmaceutical Co., Ltd (Kami Factory)

Active Ingredients

Cinacalcet hydrochloride 27.55 mg eqv. Cinacalcet

25 mg

Cinacalcet

Documents

Package Inserts

Regpara Tablet PI.pdf

Approved: April 6, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

REGPARA TABLETS 25 MG - HSA Approval | MedPath